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Background: A key treatment for acute ischaemic stroke is thrombolysis (rtPA). However, treatment is not devoid
of side effects and patients are carefully selected. AVERT (A Very Early Rehabilitation Trial), a large, ongoing
international phase III trial, tests whether starting out of bed activity within 24 hours of stroke onset improves
outcome. Patients treated with rtPA can be recruited if the physician allows (447 included to date). This study
aimed to identify factors that might influence the inclusion of rtPA treated patients in AVERT.
Methods: Data from all patients thrombolysed at Austin Health, Australia, between September 2007 and
December 2011 were retrospectively extracted from medical records. Factors of interest included: demographic
and stroke characteristics, 24 hour clinical response to rtPA treatment, cerebral imaging and process factors
(day and time of admission).
Results: 211 patients received rtPA at Austin Health and 50 (24%) were recruited to AVERT (AVERT). Of the
161 patients not recruited, 105 (65%) were eligible, and could potentially have been included (pot-AVERT).
There were no significant differences in demographics, Oxfordshire classification or stroke severity (NIHSS) on
admission between groups. Size and localization of stroke on imaging and symptomatic intracerebral heamorrhage
rate did not differ. Patients included in AVERT showed less change in NIHSS 24 hours post rtPA (median change = 1,
IQR (−1,4)) than those in the pot-AVERT group (median change = 3, IQR (0,6)) by the median difference of 2 points
(95%CI:0.3; p = 0.03). A higher proportion of rtPA treated AVERT patients were admitted on weekdays (p = 0.04).
Conclusion: Excluding a possible clinical instability, no significant clinical differences were identified between
thrombolysed patients included in AVERT and those who were not. Over 500 AVERT patients will be treated with
rtPA at trial end. These results suggest we may be able to generalize findings to other rtPA treated patients beyond
the trial population.
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Stroke is one of the leading causes of death in the devel-
oped world today and for those who survive the event,
chronic disability is a frequent complication [1]. Best
practice clinical guidelines recommend two key treat-
ments for acute ischemic stroke: care in a specialized
stroke unit and thrombolysis with recombinant-tissue
plasminogen activator (rtPA) [2,3]. Stroke unit care
(SUC) improves outcomes such as physical independence
and increases chances of survival after stroke [4]. The
most specific and biologically powerful treatment for
acute ischemic stroke is thrombolysis with rtPA given
within the first 4.5 hours of ischemic stroke onset [5,6].
However, thrombolysis is not devoid of side effects and
patients are carefully selected [7,8]. Prominent among
concerns is the fear of secondary symptomatic intracra-
nial hemorrhage (sICH), which is one major reason pre-
venting an extension of rtPA treatment to a broader
spectrum of patients [9,10].
SUC is characterized by close monitoring of physio-
logical and neurological parameters and possible compli-
cations, hydration and nutritional intake, and early
rehabilitation [11,12]. The initiation of rehabilitation has
been suggested to be of importance both to prevent and
treat complications [13] and to improve recovery of walk-
ing [14]. Although SUC improves outcomes after stroke
[15], several components of SUC are ill-defined and early
mobilization (out of bed activity training), often part of
the early rehabilitation package, is one of these. Early
mobilization is currently being tested as part of an inter-
national clinical trial, AVERT (A Very Early Rehabilitation
Trial). AVERT is a large phase III randomized controlled
trial testing whether very early mobilization (VEM) re-
duces death and disability at three months post stroke.
VEM is defined as mobilization out of bed commenced
within 24 hours of stroke onset and continued frequently
thereafter. This intervention is performed by a physiother-
apist or nurse. Participants randomized to the control arm
undergo standard stroke unit care. As rtPA is part of
standard care, patients treated with rtPA can be included
in the trial if the physician allows [16].
Mobilization of thrombolysed patients concerns some
clinicians, and rtPA protocols often include 24 hours of
bed rest after treatment. In a previous case-crossover
designed study with hypothetical case vignettes, we ex-
plored the factors likely to influence the decision to
allow patients to mobilize early after treatment with rtPA.
The study of fifty-four clinicians found that perceived risk
of neurological decline, especially due to sICH; infection
of unknown cause; severe chest infection; severe stroke
(NIHSS >20); drowsiness and confusion were factors that
significantly influenced the decision to mobilize [17]. In
reality we know little about what influences these decisions
in every day practice.Twenty three percent of the 1898 patients recruited to
AVERT to date have been treated with rtPA (n = 447).
Over 500 patients treated with rtPA are expected to be
recruited by trial end, approximately half of whom will
be mobilized within 24 hours of stroke. These data may
broaden our understanding of the benefits or harms of
combining these two treatments. However, as inclusion
in AVERT is dependent on physician approval, it is likely
that included patients will be selected, thus limiting our
ability to generalize findings to a broader stroke popula-
tion. The aim of this study therefore, was to compare
the characteristics of rtPA treated patients in the AVERT
trial with those not included, and to explore the factors
influencing inclusion in the trial.
We hypothesized that the use of rtPA would create a
selection bias in the AVERT recruitment process and
therefore that thrombolysed patients included in AVERT
would be different from the ones not included in the
trial.
Methods
Study design and subjects
A retrospective audit of patient records from our largest
recruiting site, Austin Health, Melbourne, Australia, was
conducted. Austin Health is a large metropolitan teaching
hospital and the pioneer site for AVERT. Thrombolysed
patients have been recruited on site since the beginning
of AVERT. The audit was approved by the Austin Health
Human Research Ethics Committee.
Procedure
The first AVERT patient treated with rtPA was recruited
at Austin Health in September 2007. All patients treated
with rtPA at this site between September 2007 and
December 2011 were identified from the rtPA register on
the stroke unit and the Australian Stroke Clinical Registry
(AuSCR) [18]. Patients recruited to AVERT from Austin
Health were identified through the AVERT database; re-
searchers were blinded to participants’ group allocation.
Medical records were retrieved and data extracted by two
assessors independently. Both assessors extracted data
from the same 10 clinical cases to confirm reliability of
the procedure. Brain images were reviewed electronically
in consultation with a neurologist, to determine stroke
size and localization and the presence of hemorrhagic
transformation.
Data of interest
We wanted to examine three core data themes that
might influence inclusion in AVERT: 1) patient demo-
graphics and stroke characteristics; 2) rtPA administra-
tion information (stroke to needle time) and patient
response to treatment at 24 hours post thrombolysis and
3) time and day of admission, which may influence trial
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graphics of interest included age, sex, marital status, liv-
ing arrangements on admission and country of birth.
Premorbid physical state was assessed by means of the
modified Rankin Scale (mRS) [19], and past medical his-
tory was recorded. Time and date of stroke symptoms
onset were recorded, and the clinical presentation of the
stroke was described using the Oxfordshire Classification
[20] and the National Institutes of Health Stroke Scale
(NIHSS) [21] on admission. In cases of a missing NIHSS,
the score was estimated by review of medical records by
two NIHSS-certified assessors. Stroke size and localisation
were recorded from CT/MRI scans and scored as large
cortical, small cortical, hemispheric lacunar, brainstem,
cerebellar, hemispheric large subcortical or other type of
stroke. A large cortical infarction was defined as involving
the cerebral cortex, deep white matter and/or basal ganglia
while a small cortical infarction only involved the cerebral
cortex. Time, date and type of all scans relevant to the ad-
mission were noted. The time and date of rtPA injection
was recorded as well as blood pressure, blood glucose
level, heart rate, respiratory rate, oxygen saturation and
temperature on admission and 24 hours after thromboly-
sis. The NIHSS at 24 hours post rtPA was also recorded.
Complications 24 hours after thrombolysis, such as
hemorrhagic transformation, bleeding of other origin, in-
fection or deep venous thrombosis (as noted in medical
record) were recorded. Hemorrhagic transformation was
defined as any blood seen in the brain on imaging, while
sICH was defined as the presence of blood at any site in
the brain on CT or MRI scan, in combination with clinical
deterioration of 4 points or more in NIHSS score [22]. If
performed, date and results of carotid Duplex ultrasound
were recorded. Time and date of hospital admission were
noted for all patients. In regard to AVERT inclusion cri-
teria [16], weekend admission was defined as admission
between Friday 4 pm and Sunday 12 noon.
Data analysis
Following a heuristic approach, a sample size of 150 was
estimated to be large enough to allow for the differ-
entiation of the multiple independent variables in the
planned regression analysis [23].
Patient demographics, past medical history and details
about current stroke were summarised using descrip-
tive statistics. We used the AVERT inclusion and exclu-
sion criteria (Table 1) to divide the population into three
groups: 1) patients included in AVERT after rtPA
(AVERT), 2) potential AVERT participants (pot-AVERT),
i.e., patients treated with rtPA who were eligible but not
recruited into AVERT, and 3) patients who did not meet
AVERT inclusion criteria.
The differences between AVERT and pot-AVERT pa-
tients were examined either by Wilcoxon-Mann–WhitneyRank Sum test or Fisher exact test depending on the nature
of underlying distributions. Corresponding effect sizes were
estimated using Hodges-Lehmann nonparametric shift es-
timator and Odd Ratios respectively with corresponding
95% confidence interval. For all statistical testing, the
threshold of p < 0.05 was used for determining statistical
significance. No multiplicity correction was undertaken as
we were prepared to tolerate higher values of Type I error
in order to make sure no difference between the two
groups were missed. We planned to conduct a multiple
logistic regression, including those factors shown to be sig-
nificantly different between groups in the invariable ana-
lysis. STATA ICv12 was used for all analyses of between
group comparisons.
Results and discussion
Between September 2007 and December 2011, 211 pa-
tients were treated with rtPA at Austin Health. Fifty
(24%) were recruited to AVERT (here after known as
“AVERT” group). Of the 161 patients not recruited,
105 (65%) were eligible according to the AVERT inclu-
sion criteria and could potentially have been included in
the trial (“pot-AVERT”) (Figure 1 and Table 2).
The overall rtPA treated population (44% women,
56% men) had a mean age of 74.3 years. A similar sex
and age distribution were seen in both AVERT and pot-
AVERT groups. Similarly, no significant difference was
found between these two groups in terms of past medical
history, NIHSS score on admission and Oxfordshire clas-
sification. All patients had a CT scan performed on ad-
mission and all patients, except one in pot-AVERT who
died within 24 hours, had at least one follow up scan. No
significant difference between the groups was found
regarding infarction size or location. On admission the
median NIHSS scores were similar for the AVERT (10.5,
IQR 6–18) and pot-AVERT groups (11, IQR 6–17). A sig-
nificant difference was identified in terms of NIHSS at
24 hours after rtPA between the AVERT and pot-AVERT
groups, with median scores of 8.5 (IQR 5–14) and 5.5
(IQR 2–12) respectively, (p = 0.04; Table 3).
Change in stroke severity, the difference between
NIHSS on admission and NIHSS at 24 hours post rtPA
(ΔNIHSS), varied between groups (Figure 2). Patients in-
cluded in AVERT showed less change in stroke severity;
median change = 1, IQR (−1,4)) than those in the pot-
AVERT group (median change = 3, IQR (0,6)) by the me-
dian difference of 2 points (95% CI:0–3; p = 0.03). In the
pot-AVERT group, ΔNIHSS ranged from −17 (showing an
improvement of 17 points) to +17. Fifty (48%) pot-AVERT
patients improved by ≥4 points and 11 (10%) worsened by
the same value. In contrast, in the AVERT group, ΔNIHSS
varied from +9 to −8. Fourteen (28%) AVERT patients
improved and 4 (8%) deteriorated by 4 points or more, the
remainder of the patients did not change.
Table 1 AVERT inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
• 18 years or older • Premorbid modified Rankin Score of 3, 4 or 5
• Recruited within 24 hours of stroke onset • Deterioration within first hour of admission, resulting in direct admission to ICU,
a documented clinical decision for palliative treatment, or immediate surgery
• Admitted to stroke care unit
• Conscious – reacts to verbal commands as a minimum • Concurrent diagnosis of rapidly deteriorating disease (e.g. terminal cancer)
• Unstable coronary or other medical condition judged by investigator to impose
hazard to patient if involved in trial
• Systolic blood pressure < 110 or > 220 mmHg
• Oxygen saturation < 92% (±supplemental oxygen)
• Resting heart rate < 40 or >110 bpm
• Temperature > 38.5°C
• Enrolled in another intervention trial
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and after 24 hours were not significantly different be-
tween the AVERT and pot-AVERT groups. Similar re-
sults were found for complications after thrombolysis.
Neither hemorrhagic brain transformation, symptomatic
intracranial haemorrhage, bleeding of other origin, deep
venous thrombosis, nor infection varied between groups
(Table 3). A regression analysis was not warranted.
Carotid Doppler ultrasound was performed in 84% of
the AVERT patients and in 89% of the pot-AVERT pa-
tients. Thirty five percent of patients in each group had the
examination performed within 24 hours. No significant dif-
ferences were found in terms of presence of stenosis of any
grade between the two groups. Of the patients who under-
went Duplex ultrasound, 40% of AVERT and 32% of pot-
AVERT had any degree of stenosis.
The rate of admission during the weekend was differ-
ent between the groups (p = 0.04), with 12% of AVERT
and 27% pot-AVERT patients admitted during that time.
In contrast to our original hypothesis, we found that
thrombolysed patients recruited to the AVERT trial didFigure 1 Patients selection: flow chart representing the patients revienot differ significantly at inclusion from those who were
not included. Patients in both groups showed similar
median NIHSS on admission. Instead, we identified a
significant NIHSS change at 24 hours post thrombolysis,
with AVERT patients on average changing less. The tigh-
ter distribution of ΔNIHSS score in the AVERT group
could indicate that recruited patients were in a more
stable state, without extremes in improvement or severe
worsening within the first 24 hours post thrombolysis.
This may have prompted physicians to agree to their re-
cruitment in a clinical trial of mobilization. In contrast,
50% of the pot-AVERT patients improved or deterio-
rated by as much as 17 points on the NIHSS. Marked
improvements in NIHSS might have prompted physi-
cians to plan discharge early, while marked deterioration
could have raised concerns regarding study inclusion. It is
important to note that those recruited to AVERT (n = 50)
were randomised to control or intervention, and that
those randomised to the intervention (early mobilization)
may have started within 24 hours of stroke onset. This
may have contributed to the 24 hour NIHSS change. Thew and classification regarding AVERT inclusion/exclusion criteria.
Table 2 Patients characteristics on admission
Variable potAVERT (n = 105) AVERT (n = 50) Effect size* (95% CI) p
Age (years)
Mean (±SD) 73 (±13.6) 75 (±12.6) 2.25 (−1.18-5.60) 0.17
Sex
Female 47 (45%) 23 (46%) 1.05 (0.54-2.06) >0.99
Past medical history
Hypertension 64 (61%) 38 (76%) 2.03 (0.96-4.28) 0.07
Diabetes 21 (20%) 16 (32%) 1.88 (0.89-4.01) 0.11
High cholesterol 47 (45%) 23 (46%) 1.05 (0.54-2.06) >0.99
Peripheral vascular disease 4 (3.8%) 0 0 0 (0–2.00) 0.31
Ischaemic heart disease 22 (21%) 10 (20%) .94 (0.42-2.15) >0.99
Angina 6 (5.7%) 2 (4.0%) 0.69 (0–3.12) >0.99
Arthritis (lower limb) 6 (5.7%) 4 (8.0%) 1.42 (0.41-4.94) 0.73
Lower limb joint replacement 4 (3.8%) 2 (4.0%) 1.05 (0–5.12) >0.99
Emphysema or COPD 5 (4.8%) 1 (2.0%) 0.41 (0–2.74) 0.67
Atrial fibrillation 25 (24%) 14 (28%) 1.24 (0.59-2.65) 0.69
Premorbid mRS
Independent (mRS 0–2) 105 (100%) 50 (100%) N/A >0.99
NIHSS On admission
Median (IQR) 11 (6–17) 10.5 (6–18) 0 (−2-2) 0.91
Oxfordshire
TACI 33 (31%) 24 (48%)
PACI 48 (46%) 22 (44%) 0.09
POCI 7 (6.7%) 1 (2.0%)
LACI 17 (16%) 3 (6.0%)
Imaging
Large cortical 56 (53%) 32 (64%)
Small cortical 6 (5.7%) 1 (2.0%)
Hemispheric lacunar 6 (5.7%) 3 (6.0%)
Brain stem 6 (5.7%) 0 0 0.49
Cerebellum 1 (1.0%) 0 0
Hemispheric non cortical 12 (11%) 4 (8.0%)
Other 1 (1.0%) 0 0
*Effect sizes expressed as H-L for continuous and OR for binary.
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approximately 17 hours post stroke.
Based on the differences in NIHSS score before treat-
ment and 24 hours after thrombolysis, patients may be
divided into the “golden responders” with a great im-
provement in NIHSS score after thrombolysis, and the
“non-responders” which include those with a severe
stroke who keep deteriorating, or those with a severe
stroke with little improvement after thrombolysis. Our
results indicate that patients who show little improve-
ment appear to be recruited in a higher proportion to
AVERT. Such patients might be considered to have thepossibility to regain more function in a rehabilitation
trial, and are therefore recruited more frequently. The
“golden responders” on the other hand, might be consid-
ered not to be in need of rehabilitation since they
already do very well. Finally, patients with an extremely
severe stroke and poor prognosis might be considered to
be in a critical situation where rehabilitation will not
have any benefit, or may even be harmful. These patients
are generally not recruited to clinical trials.
In our previous study [17], we found that complica-
tions such as infection and sICH were factors that po-
tentially influenced the decision to mobilize or prescribe
Table 3 Patients characteristics at time of thrombolysis and 24 hours after thrombolysis
Variable potAVERT (n = 105) AVERT (n = 50) Effect size* (95%CI) p
Stroke to needle (min)
Median (IQR) 138 (108–156) 126 (108–156) −1.2 (−15-13.2) 0.88
NIHSS
At 24 hours
Median (IQR) 5.5 (2–12) 8.5 (5–14) 2 (0–5) 0.04
Physiological data at thrombolysis
Hypertension 31 (62%) 66 (63%) 0.96 (0.48-1.92) >0.99
Hypotension 0 0 1 (2.0%) N/A 0.32
Hyperglycaemia 3 (3.3%) 2 (4.6%) 1.41 (0–7.38) 0.66
Hypoglycaemia 0 0 2 (4.6%) N/A 0.10
Bradycardia 13 (12%) 10 (20%) 1.77 (0.73-4.30) 0.23
Tachycardia 9 (8.6%) 4 (8.0%) 0.93 (0.29-3.01) >0.99
Arythmia 24 (25%) 15 (33%) 1.48 (0.69-3.18) 0.32
Rapid atrial fibrillation 5 (4.9%) 3 (6.0%) 1.24 (0.31-4.92) 0.72
Hypoxia 1 (1.0%) 0 0 N/A >0.99
Complications at 24 h post thrombolysis
Hemorrhagic transformation 14 (13%) 10 (20%) 1.63 (0.68-3.91) 0.34
sICH 0 0 1 (2.0%) N/A 0.32
Bleeding other than cerebral 12 (11%) 3 (6.0%) 0.49 (0.14-1.7) 0.39
DVT 1 (1.0%) 1 (2.0%) 2.12 (0) 0.54
Infection 9 (8.6%) 6 (12%) 1.45 (0.51-4.19) 0.56
*Effect sizes expressed as H-L for continuous and OR for binary.
Hypertension is defined as a blood pressure (BP) > 140/90 mmHg; hypotension: BP < 90/60 mmHg; hyperglycaemia; blood sugar level (BSL) > 13.5 mmol/L;
hypoglycaemia: BSL < 4.0 mmol/L; bradycardia: heart rate < 60 beats per minute (bpm); tachycardia > 100 bpm; hypoxia: O2 saturation < 90%.
Figure 2 Change of NIHSS between groups: box plot comparing the distribution of the change in NIHSS from admission to 24 hours
after thrombolysis (ΔNIHSS) between the two subgroups.
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explored complications were different between included
patients and eligible, but not included, patients.
We included carotid Duplex timing and findings in
this study because in some centres, vessel occlusion
might be considered prior to allowing patients to get out
of bed for the first time. In Australia, this is not the
norm. As only 35% of the patients in both groups had
the examination done within 24 hours, the carotid Duplex
results were unlikely to impact the decision for early
mobilization and therefore inclusion into the trial.
We elected to explore a range of factors that might
influence inclusion in a clinical trial, based on previous
research [17], clinical experience and our experience
with recruitment challenges in this clinical trial. These
may not be the only factors influencing recruitment to
the trial. Physician opinion was not explored in this
study. Physicians at the Austin do not follow a 24 hour
rest in bed protocol and reported that they rarely, if ever,
say no to eligible patients treated with rtPA participat-
ing in the trial. Nevertheless, unconscious bias may
have been a factor. Participant refusal to participate in
the trial and recruitment to another intervention trial
might have contributed to the non enrolment of eligible
thrombolysed patients into AVERT. AVERT screening
logs show a refusal rate of less than 3% of approached
patients. Therefore refusal to participate cannot be con-
sidered as the main reason for non recruitment of eligible
thrombolysed patients.
A limitation of this study may be that in cases where
the NIHSS was not recorded at the 24 hour post stroke
time point, assessors were required to extract NIHSS
from the clinical notes. However, it has been shown in
previous studies that such a method has a high degree of
validity and reliability [24,25]. Since the same rating con-
ditions were applied for all patients, regardless of their
recruitment to AVERT, comparisons between the groups
should not have been affected by this procedure.
Austin Health, the pioneer site for AVERT, is the high-
est recruiting centre for the trial. Even though our study
focused on a single site, it provided a large sample of pa-
tients to allow exploration of selected factors. AVERT
was running at 44 participating hospitals worldwide dur-
ing the studied period, with rtPA treated patients re-
cruited from 23 hospitals.
In terms of non patient related factors that could
affect recruitment, we expected a difference between
the groups regarding the time and day of admission.
Indeed, thrombolysed patients admitted during the
weekends were significantly less likely to be recruited
to AVERT. The lower recruitment rate occurring during
the weekends is explained by the unavailability of study
personnel, who in this trial are staff physiotherapists and
nurses.Conclusion
Excluding a neurological instability, no significant clin-
ical differences were identified between thrombolysed
patients included in AVERT and those who were not.
These results suggest that efficacy results from rtPA
treated patients in the completed trial (expected sample
500 patients) may be generalizable to the broader popu-
lation of people treated with rtPA.
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